G. Aliev President "GALLY" International Biomedical Research Consulting LLC San Antonio, TX USA
Dr. Gjumrakch Aliev received his MD in 1982 from the Baku Medical University (former USSR) with cum laude. Then, he accomplished his Ph.D. in Cardiovascular Diseases from the prestigious Russian Academy of the Medical Sciences, Moscow, Russia in 1989 with cum laude. He received postdoctoral training with Professor G. Burnstock at the University College of London. He authored and co-authored more than 500 publications in the fields of neurodegenerative disease research (Alzheimer's disease), as well as cardio-and cerebrovascular disease, cancer, and electron microscopy. He is an outstanding teacher, scholar, and a renowned scientist in the area of cellular.
L. Feng WuXi PharmaTech Co., Ltd. Wuhan China
Dr. Lian-Shun Feng obtained his PhD degree from Tsinghua University in 2011, and then
worked as postdoctorial researcher in Peking University. Currently, Dr. Lian-Shun Feng work in
WuXi AppTec as principal investigator. In 2017 and 2018, around 20 peer-reviewed SCI papers
were published, and many of them were cited over 100 times in two years.
B. Li The Second Hospital of Jilin University Changchun China
Dr. Bingjin Li is a graduate of Yanbian University, China. She received her Ph.D. from Ehime University, Japan. She performed postdoc training at Washington State University and is a full professor at the second hospital of Jilin University, China. Her lab uses behavioral and electrophysiological analyses to explore the underlying relationship between neuronal function and behavior. This integrative approach involves the use of molecular biology, biochemistry, immunocytohistochemistry, neurophysiology, anatomy, and a wide range of behavioral methodology to understand the function of the nervous system.
X. Luo The first affiliated hospital of Xiamen university Fujian China
Dr. Luo got his PhD degree and received the postdoctoral training at central south university. Then he worked as a research assistant at the Chinese university of Hong Kong. In 2017, he joined the first affiliated hospital of Xiamen university. His research interests focus on the field of clinical pharmacology, including clinical pharmacokinetics, pharmacodynamics and clinical phase I of new drugs. He has had over 10 years’ experience in the development of biomarkers in personalized medicine in a variety of disorders, such as cancer, transplantation, etc. Currently, he has responsible for more than 50 clinical phase I studies.
D.S. Stoyanov Medical University of Plovdiv Plovdiv Bulgaria
Dr Drozdstoy Stoyanov holds currently the academic position of Full Professor and Head,
Neuropsychiatry and Brain Imaging Group, Medical University, Plovdiv.
He is Vice Chair of Philosophy SIG, Royal College of Psychiatrists, UK, Visiting Fellow in the
University of Pittsburgh, USA (2009), International Distinguished Fellow of the American
Psychiatric Association (2018), Guest Lecturer in the Universities of Copenhagen (2015), Vienna
(2017) and Bergen (2018).He published more than 160 scholarly papers, including five monographs and three textbooks.
Dr Stoyanov is Associate Editor of Frontiers in Psychiatry and the European Journal of Person
Centered Health Care; Editorial Board member of Dialogues in Philosophy, Mental and
Neurosciences, International Journal for Person Centered Medicine, Folia Medica and others.
Ad hoc reviewer in Current Medicinal Chemistry, Molecular Neurobiology, Human Brain Mapping,
Journal of Affective Disorders, Biotechnology and Biotechnological Equipement.
S.S. Thakur Centre for Cellular and Molecular Biology Hyderabad India
My research interests involves application of Mass Spectrometry based proteomics in Health and
Disease especially biomarker discovery and Drug Development. My group uses mass
spectrometry based high throughput quantitative proteomics, natural product chemistry, cell
biology, animal model, stem cell, and modern biology approach to find the target, to develop
novel drugs and elucidate its mode of action against cancer and other metabolic disorders such as
diabetes. Cancer is a hyperplastic condition that leads to uncontrolled proliferation, invasion,
metastasis, dysregulation of apoptosis and cell cycle. Cancer is the second leading cause of
worldwide human mortality after cardiovascular diseases. We are investigating the efficacy of
various natural and synthetic metabolites on melanoma, retinoblastoma, leukaemia, and lung
cancer using in vitro and in vivo method including animal model. Further, investigating the
molecular basis for Cell adhesion, AKT signalling and tyrosine kinase associated cancer
progression and response and resistance to targeted therapy in these cancers is in progress in my
Allen B. Reitz Fox Chase Chemical Diversity Center, Inc. Doylestown, PA USA
Dr. Reitz obtained a doctorate (Ph.D.) in Chemistry from the University of California, San Diego. Dr. Reitz also holds an Executive Masters in Technology Management from the University of Pennsylvania (Wharton, Penn Engineering).
Currently Dr. Reitz is also an Adjunct Professor in the Drexel University College of Medicine. He has published more than 150 scientific publications and is a named inventor of 60 issued U.S patents.
Dr. Reitz was the founding Editor (2000) and is currently the Editor-in-Chief of this journal (Current Topics in Medicinal Chemistry, CTMC), published by Bentham Science Publishers.